The platform has the potential to bring down times and costs of drug development by focusing on already approved, discontinued, shelved or investigational therapeutics.
The EU-funded platform - REMEDI4ALL – has been launched with the aim of gathering expertise in order to address the existing complexities of drug repurposing. The platform is funded under the Horizon Europe programme and it comprises 24 organisations in the fields of clinical and translational research, clinical operations, patient engagement and education, regulatory framework, funding, governance, Health Technology Assessment (HTA) and pricing and reimbursement collaborating under the leadership of the European infrastructure for translational medicine (EATRIS).
REMEDi4ALL aims at:
REMEDi4ALL has selected four medicine repurposing projects in different stages of development to demonstrate the viability of the newly created platform. Each project covers a different therapeutic area with high unmet medical needs pancreatic cancer, COVID-19, rare diseases and ultra-rare diseases. These projects will first be onboarded to ensure a patient-centric approach before testing all elements of the platform to optimise its tools and services.
Full information on the project can be found here